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We studied seven genes that reflect events relevant to antidepressant action at four sequential
levels: (1) entry into the brain, (2) binding to monoaminergic transporters, and (3) distal effects
at the transcription level, resulting in (4) changes in neurotrophin and neuropeptide receptors.
Those genes are ATP-binding cassette subfamily B member 1 (ABCB1), the noradrenaline,
dopamine, and serotonin transporters (SLC6A2, SLC6A3 and SLC6A4), cyclic AMP-responsive
element binding protein 1 (CREB1), corticotropin-releasing hormone receptor 1 (CRHR1) and
neurotrophic tyrosine kinase type 2 receptor (NTRK2). Sequence variability for those genes
was obtained in exonic and flanking regions. A total of 56280000bp across were sequenced in
536 unrelated Mexican Americans from Los Angeles (264 controls and 272 major depressive
disorder (MDD)). We detected in those individuals 419 single nucleotide polymorphisms
(SNPs); the nucleotide diversity was 0.00054±0.0001. Of those, a total of 204 novel SNPs were
identified, corresponding to 49% of all previously reported SNPs in those genes: 72 were in
untranslated regions, 19 were in coding sequences of which 7 were non-synonymous, 86 were
intronic and 27 were in upstream/downstream regions. Several SNPs or haplotypes in ABCB1,
SLC6A2, SLC6A3, SLC6A4, CREB1 and NTRK2 were associated with MDD, and in ABCB1,
SLC6A2 and NTRK2 with antidepressant response. After controlling for age, gender and
baseline 21-item Hamilton Depression Rating Scale (HAM-D21) score, as well as correcting for
multiple testing, the relative reduction of HAM-D21 score remained significantly associated
with two NTRK2-coding SNPs (rs2289657 and rs56142442) and the haplotype CAG at rs2289658
(splice site), rs2289657 and rs2289656. Further studies in larger independent samples will be
needed to confirm these associations. Our data indicate that extensive assessment of
sequence variability may contribute to increase understanding of disease susceptibility and
drug response. Moreover, these results highlight the importance of direct re-sequencing of key
candidate genes in ethnic minority groups in order to discover novel genetic variants that
cannot be simply inferred from existing databases.
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Introduction
Major depressive disorder (MDD) is a common,
complex and recurrent disorder of gene–environment
interactions. The estimated heritability may range
from 0.36 to 0.66.
1,2 Following up on previous study
on the pathophysiology of MDD and on the prevailing
hypotheses for treatment response, we sought to
identify genes that influence susceptibility for MDD
or treatment response in the central nervous system
pathways relevant to stress reactivity and to the
pathways of action of antidepressant drugs. Current
data point out to roles for genes involved in drug
transport, serotonin neurotransmission, neurotrophin
signaling and response to stress. Promising linkage
results are located in several chromosomes,
3 which
highlight the multilocus nature of the genetic vulner-
ability to MDD.
Recently, rapid technological advances have started
unraveling the contributions of common (frequency
>1%) and rare genetic variants in complex disorders.
In a topical review, Bodmer and Bonilla
4 have
synthesized current views, implications and
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disease–common variant and common disease–rare
variant. For most common variants, the disease-
associated variant is unlikely to be functionally
relevant; it may be closely linked to the functional
variant, and it will cause a small increase in disease
risk (odds ratio smaller than 2, generally between 1.1
and 1.4). In contrast, rare variants generally have
functional and large phenotypic effects; in many
cases they are missense variants that reflect amino-
acid changes relevant to protein–protein interactions.
Diverse scenarios may occur in the pathophysiology
of common complex disorders: Common variants may
be modifiers of genes with rare variant effects, such as
recently described for the MC4R gene.
5 Moreover,
areas near common variants may contain candidate
genes in which there are rare variants. The identifica-
tion of rare variants may significantly affect our
understanding of complex disease etiology.
We re-sequenced seven candidate genes of impor-
tance in the pathophysiology of MDD.
6 Conceptually,
we sought a group of genes that reflects a sequence of
events relevant to drug action at four levels: (1) entry
into the brain, (2) binding to monoaminergic trans-
porters, and (3) distal effects at the transcription level,
resulting in (4) changes in neurotrophin and neuro-
peptide receptors. Specifically, we studied a blood–
brain barrier drug transporter pump (ACCB1, also
called MDR1), which regulates drug entry into the
brain (level 1), the norepinephrine, dopamine, and
serotonin transporters (SCL6A2, SLC6A3 and SL6A4)
(level 2), an antidepressant-regulated transcription
factor (cyclic AMP-responsive element binding pro-
tein 1 (CREB1)) (level 3) and two receptors (level 4):
neurotrophic tyrosine kinase type 2 receptor
(NTRK2), important in synaptic function and neural
plasticity, and corticotropin-releasing hormone recep-
tor 1 (CRHR1), which regulates the response to stress
at the behavioral, neuroimmune and neuroendo-
crine—hypothalamic–pituitary–adrenalaxis levels.
Materials and methods
Patients and controls
The study consisted of 272 patients (66% female,
34% male; mean age: 38±10) with MDD and 264
healthy control individuals (60% female, 40% male;
average age: 36±11). MDD was defined as a DSM-IV
(Diagnostic and Statistical Manual of Mental Dis-
orders, 4th Edition) diagnosis of current, unipolar
major depressive episode and a 21-item Hamilton
Depression Rating Scale (HAM-D21) score of X18
with item number 1 (depressed mood) rated X2. All
MDD patients were screened for the pharmacogenetic
study of antidepressant treatment response as pre-
viously described.
7 All MDD patients had compre-
hensive psychiatric and medical assessments in their
primary language, on the basis of diagnostic and
ratings instruments that had been fully validated in
English and in Spanish. Exclusion criteria included
active medical illnesses that could be etiologically
related to the ongoing depressive episode, current or
active suicidal ideation with a plan and strong intent,
pregnancy, lactation, current use of medications with
significant central nervous system activity, which
interfere with electroencephalogram (EEG) activity
(for example, benzodiazepines) or any other antide-
pressant treatment within the 2 weeks before enroll-
ment, illicit drug use and/or alcohol abuse in the last
3 months or current enrollment in psychotherapy. All
MDD patients were Mexican-Americans and had at
least three grandparents born in Mexico.
All patients had an initial comprehensive psychia-
tric and medical assessment and, if enrolled in the
pharmacogenetic study of antidepressant treatment
response, had weekly structured follow-up assess-
ments for 9 weeks. The study consisted of two phases:
a 1-week single-blind placebo lead-in phase to
minimize the impact of placebo responders followed,
if subjects continued to meet the inclusion criteria
after phase 1, by random assignment to one of the
two treatment groups: fluoxetine 10–40mg per day or
desipramine 50–200mg per day, administered in a
double-blind manner for 8 weeks. Our primary
clinical outcome measure was HAM-D21 score and
clinical remission on antidepressants was defined
as having a final (week 8) HAM-D21 score <8. In
addition, the relative response change was also
computed as the difference in HAM-D21 score
between pre- and post-treatment divided by the
pretreatment HAM-D21 score.
Age-, gender- and ethnicity-matched healthy con-
trol individuals were recruited from the same Mex-
ican-American community in Los Angeles by the
same bilingual clinical research team. Controls for our
genomic studies were in general good health but were
not screened for medical or psychiatric illness.
Genomic DNA collection, amplification and
sequencing
At the initial visit, after informed consent was
obtained from the participating individuals, blood
samples were collected into EDTA (K2EDTA) BD
Vacutainer EDTA tubes (Becton Dickinson, Franklin
Lakes, NJ, USA), and genomic DNA was isolated by
using Gentra Puregene DNA purification kits (Gentra
Systems, Indianapolis, IN, USA). DNA sequencing for
seven genes was carried out in collaboration with the
Sanger Institute by following ExoSeq protocol (http://
www.sanger.ac.uk/humgen/exoseq/). Briefly, the
known protein-coding regions, novel coding
sequences and transcripts, exons and their flanking
sequence were extracted from the Vega database
(http://vega.sanger.ac.uk/index.html). Primers were
designed automatically using Primer3 (http://frodo.
wi.mit.edu/) to amplify DNA and primer pairs were
checked for uniqueness before ordering and pre-
screened to determine the optimum conditions for
amplification. After amplification, a sample of the
products were visualized on an agarose gel to confirm
the size of the PCR product. The remaining PCR
product was then cleaned up using two enzymes,
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Bidirectional sequencing of amplicons was carried
out using Big DyeTM chemistry (Big Dye Terminator,
Version 3.1; Applied Biosystems, Foster City, CA,
USA). Single nucleotide polymorphisms (SNPs) were
called using ExoTrace http://www.sanger.ac.uk/
humgen/exoseq/analysis.shtml, a novel algorithm
developed in-house for the detection of heterozygotes
in sequence traces , which processes the sense and
antisense sequence reads separately and subse-
quently, and combines the results to allow SNP
scoring. All polymorphisms reported here had a
genotyping rate of X80% and an average nucleotide
call rate of 93%.
Genomic control genotyping
To detect potential bias due to population stratifica-
tion, two approaches were used to test for hidden
stratification in our data. First, 54 independent SNPs
across 22 autosomal chromosomes were selected to
analyze a combined sample using the genotype data
download from three HapMap ethnic samples using
STRUCTURE program (http://pritch.bsd.uchicago.
edu/software.html)
8,9 and showed that three distinct
clusters were well identified with an average propor-
tion of at least 92% of individuals correctly assigned
to the given ethnic populations (CEU, CHBþJPT,
YRI). This panel of SNPs were then used as genomic
control to test our sample and showed an almost
equal proportion assigned to each clusters, given
K=2, 3, 4 in both cases and controls. Second, geno-
type frequencies from each of the 54 unlinked SNPs
were also compared between cases and controls using
the method described by Pritchard and Rosenberg
10
and no significant difference was found based on an
overall test statistic (w
2=100.50, d.f.=108, P=0.68).
Therefore, no population stratification adjustment
was necessary for our association analyses.
Nucleotide diversity, population differentiation and
Hardy–Weinberg equilibrium
Nucleotide diversity (y) and its standard deviation
(S(y)) were calculated under the assumption of an
infinite neutral allele model,
11,12 and all calculations
were based on n=946 for all the sites given that the
average sample size was 473 individuals across all the
polymorphisms. Population differentiation estima-
tion was based on the pairwise FST values for the
dbSNPs (single nucleotide polymorphism database
hosted at the National Center for Biotechnology
Information), which were both detected in our
Mexican-American sample and reported in HapMap
sample. FST values were calculated as described
byWeir,
13 Weir and Cockerham,
14 and Weir and Hill.
15
In order to compare allele frequencies and to be able
to treat chromosomes as independent observations,
the genotype frequencies must be in Hardy–Weinberg
equilibrium (HWE).
16 Exact testing of HWE was
performed separately for healthy controls and MDD
patients using the PLINK program Version1.00 (http://
pngu.mgh.harvard.edu/ ~purcell/plink/).
17 SNPs that
were not in HWE in the healthy control group were
excluded from the allele-based association analyses of
cases and controls.
Statistical analysis
Data preparation and descriptive statistics were
carried out with SAS software (SAS Version 9.1.3,
SAS Institute, Cary, NC, USA). For SNP-based
association analyses of case vs control or remitter vs
non-remitter, Fisher’s exact test (two-tailed) was
performed to compare allele and genotype distribu-
tions between depressed and healthy individuals
using PLINK. In the allelic association analysis, each
polymorphism was tested in controls to ensure the
fitting with HWE; the odds ratio on the 2 2
contingency table of allele counts and its 95%
confidence interval were estimated using Woolf’s
method or fitting exact logistic regression model with
SAS software when the frequency in a table cell is
zero.
18 In genotypic association analysis, SNP effects
were tested under a codominant model on the 2 3
contingency table of genotype counts.
For the quantitative outcome (relative reduction %
in HAM-D21 scores between pre- and post-treatment),
the analyses based on dominant model were per-
formed, separately, for the joint sample of patients
treated with desipramine or fluoxetine and for
medication-specific sample. General linear regression
models were used to examine the association between
genotype and relative HAM-D21 score reduction by
controlling for age, gender and baseline (pretreat-
ment) HAM-D21 score using the PLINK program. The
Benjamini and Hochberg method was used to control
for false discovery rate and the significance threshold
was set at FDR_BHp0.05
19.
For haplotype-based association analysis, Haplo-
view (Version 4.1, Broad Institute of MITand Harvard,
http://www.broad.mit.edu/mpg/haploview/), was
first used to identify the haplotype blocks by applying
the Four Gamete Rule
20 based on the SNPs with a
minor allele frequency (MAF) X0.01 in the combined
sample of cases and controls and HWE exact test
P>0.01 in controls. The PLINK program was then
used to examine the association of specific haplotype
with depression diagnosis, clinical remission, as well
as quantitative outcome of antidepressant treatment.
Results
Identification of sequence variations
A total of 419 single nucleotide sequence variants
(Table 1) were identified by re-sequencing of B105kb
of exonic sequence and their flanking regions in the
selected seven genes in an ethnically homogeneous
sample of 264 healthy controls and 272 MDD patients.
Among the 419 SNPs, 204 (49%) are novel poly-
morphisms, not previously described, including 86
in introns, 72 in untranslated regions (UTRs), 19
(12 synonymous) in coding regions, 18 in upstream
and 9 in downstream regions. Overall, 95% of the
novel polymorphisms had a MAF lower than 5%,
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Molecular Psychiatrywhereas the corresponding proportion was 57% for
dbSNPs (Supplementary Table 1). Similar distribution
of MAFs was seen between cases and controls for both
SNPs in intronic and in exonic regions (Figure 1a).
Among the 419 SNPs, the proportion of SNPs with
HWE exact test P-value X0.05 was 92% for controls
and 91% for MDD cases (Supplementary Table 1).
Nucleotide diversity was estimated for each gene
by correcting for both sample size and length of the
screened site (Table 1). Nucleotide diversities were
comparable in SLC6A3 (0.00053±0.00012), NTRK2
(0.00051±0.0001) and SLC6A2 (0.00056±0.00012),
but were lower in CREB1 (0.00032±0.00009) and
ATP-binding cassette subfamily B member 1 (ABCB1)
Figure 1 Minor allele frequency (MAF), nucleotide diversity and FST measure in seven candidate genes in Mexican-
American major depressive disorder (MDD) patients and controls. Histograms show the total number of single nucleotide
polymorphisms (SNPs) detected in intronic (black bar) and exonic (gray bar) regions in the seven genes by MAF in 272 MDD
patients and 264 healthy controls (a); the nucleotide diversity in noncoding (black bar) and coding (gray bar) (b) or intronic
(black bar) and exonic (gray bar) regions (c) by gene in the combined sample of 272 MDD patients and 264 healthy controls;
the total number of SNPs shared by Mexican-American (MA) sample and HapMap samples by pairwise FST value (d)o r
represent the average FST by gene (e) in MAvs CEU (black bar), MAvs HCB (dark gray bar), MA vs JPT (gray bar) and MA vs
YRI (White bar).
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Molecular Psychiatry(0.00038±0.00008) and appeared higher in SLC6A4
(0.00078±0.00016) and CRHR1 (0.00109±0.00024).
This led to an overall nucleotide diversity of 0.00054
for all the seven genes investigated. When the
nucleotide diversity was estimated separately for
coding and noncoding sequence, five out of seven
genes (except for SLC6A3 and ABCB1) showed higher
nucleotide diversity in noncoding regions when
compared with coding segments (Figure 1b). How-
ever, when the nucleotide diversity was estimated
separately for exonic and intronic sequence, all the
seven genes showed higher nucleotide diversity in
exonic regions than in intronic segments (Figure 1c).
This is because of the high nucleotide diversity in
untranslated regions (0.00088±0.00017).
Among the 215 dbSNPs detected, 83 were reported
in all four HapMap ethnic groups: CEU (Caucasian),
YRI (African), CHB (Han Chinese) and JPT (Japanese)
in the NCBI database as of 25 June 2008. Pairwise FST
values between Mexican Americans (MA) and each
HapMap ethnic sample were computed for the shared
83 dbSNPs. Overall, the greatest difference in allele
frequencies was found between Mexican Americans
and Africans with a highest mean FST of 0.126,
compared with mean FST of 0.035 in MA vs CEU,
0.033 in MA vs CHB and 0.032 in MA vs JPT (Figure
1d). For the gene-specific mean FST in MA vs YRI,
larger mean FST values were observed for SLC6A3
(0.208) and SLC6A4 (0.198), but much lower for
SLC6A2 (0.04) (Figure 1e).
SNP-based genetic association analyses of cases and
controls
Single nucleotide polymorphism-based allelic
and genotypic association analyses revealed that 16
polymorphisms were associated with MDD with a
nominal P<0.05 in five genes (Table 2), including
two common 30 UTR polymorphisms in NTRK2
(rs7020204 and rs2013566) and one rare 50 UTR
polymorphism in SLC6A4 (rs28914831). Among the
nine SNPs with a nominal P<0.05 in both allelic and
genotypic tests, seven were uncommon polymorph-
isms with a MAF <0.03 in controls, including
one in CREB1 (rs3732076), two in ABCB1
(rs4728697, rs58898486) and four in SLC6A4
(rs7212502, rs28914831, NT_010799.14_3288789 and
rs56355214) (Table2 and Supplementary Table 1).
Three SLC6A4 common polymorphisms (rs7224199
and rs3813034 in upstream and rs140701) showed
genotypic association, but with a small allelic odds
ratio <1.3 and allelic test nominal P>0.05. No
associated SNPs remained significant after adjusting
for multiple tests with an FDR_BH p0.05.
SNP-based genetic association analysis of
antidepressant response
In this study, there were 142 MDD patients who
enrolled in the pharmacogenetic trial and comple-
ted 8-week antidepressant treatment (68 treated with
desipramine and 74 treated with fluoxetine). For
the discrete outcome (remission vs non-remission),
SNP-based allelic or genotypic association analyses
revealed that clinical remission status was associated
with several polymorphisms in or near three genes,
ABCB1, NTRK2 and SLC6A2 (Table 3). All of the nine
associated NTRK2 SNPs were in 30 UTR or coding
regions except for rs2289658 at a splice site, whereas
the two associated SLC6A2 SNPs were in intron or
upstream region. For the ABCB1 gene, the associated
SNPs included two in UTR, two in introns and one in
coding sequence. No associated SNPs remained
significant after adjusting for multiple tests with an
FDR_BH p0.05 in the discrete outcome analysis.
For the quantitative outcome (relative reduction in
HAM-D21 score) after controlling for age, gender and
baseline HAM-D21 score, general linear regression
analyses revealed that relative reduction of HAM-D21
scores was associated with six NTRK2 SNPs (three in
30 UTR, two synonymous and one intronic at splice
site) and one SLC6A3 intronic SNP rs8179029 in
desipramine-treated patients, two SLC6A2 upstream
SNPs in fluoxetine-treated patients and one SLC6A3
intronic SNP rs8179029 for combined sample, with a
nominal P<0.01 (Table 4). Among the associated
SNPs, only two NTRK2 synonymous SNPs, rs2289657
and rs56142442, remained statistically significant
after correcting for multiple testing with an
FDR_BH=0.05 in the sample of patients treated with
desipramine. Desipramine-treated patients who are
homozygous for C allele at synonymous SNP
rs2289657 or at rs56142442 had higher levels of
improvement with 27% larger reduction in HAM-
D21 scores, compared with those who are not
homozygous for C allele at rs2289657 or rs56142442.
Haplotype-based analyses
Haplotype analysis identified a total of 17 haplotype
blocks in the seven genes using the Four Gametes
Rules with the Haploview program, including one
block in CREB1, two blocks in each of SLC6A3,
SLC6A4 and CRHR1, three blocks in each of ABCB1
and SLC6A2, and four blocks in NTRK2 (Figure 2).
For the association analysis of case and control, the
diagnosis of depression was found to be associated
with five haplotypes with a nominal P-value between
0.01 and 0.05 in CREB1, SLC6A3, ABCB1, NTRK2 and
SLC6A2. Among the five depression-associated hap-
lotypes, four included at least one SNP showing an
association with depression in the single SNP-based
analysis (Table 5). For the association of remitter
and non-remitter, eight haplotypes were found to be
associated with remission status, including two in
ABCB1 (ACA in block 1 for desipramine-treated
patients and GCGCACACGAGAC in block 2 for
fluoxetine-treated patients), two in NTRK2 (TCG and
CAG in block 3 for desipramine-treated patients), one
in SLC6A2 (GCCAGT in block 4 for desipramine-
treated patients) and three in SLC6A4 (TAGC and
TAGA in block 1 and ATTGTAACCC in block 2 for the
combined sample of desipramine- or fluoxetine-
treated patients). Among the eight remission-asso-
ciated haplotypes, three showed an association with a
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Molecular PsychiatryFigure 2 Linkage disequilibrium (LD) pattern in seven genes: cyclic AMP-responsive element binding protein 1 (CREB1)
(a), SLC6A3 (b), ATP-binding cassette subfamily B member 1 (ABCB1)( c), neurotrophic tyrosine kinase type 2 receptor
(NTRK2)( d), SLC6A2 (e), SLC6A4 (f) and corticotropin-releasing hormone receptor 1 (CRHR1)( g). Standard color scheme in
Haploview program is used to display the level of logarithm of odds (LODs) and the D0. Shown in each box are estimated
statistics of the D0, which indicates the LD relationship between each pair of single nucleotide polymorphisms (SNPs) and
are not labeled if D0 =1.00. Regions are shown in bright red, light blue, shades of pink/red and white for D0 =1þLODX2,
D0 =1þLOD<2, D0 <1þLODX2 and D0 <1þLOD<2, respectively. Vertical lines on the long horizontal white indicate the
relative positions of SNPs in the gene.
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Molecular Psychiatrynominal Pp0.01: TCG in block 3 of NTRK2 and
GCCAGT in block 4 of SLC6A2 (P=0.009) for
desipramine-treated patients, and TAGC in block 1
of SLC6A4 for fluoxetine-treated patients (P=0.004)
(Table 5).
For quantitative outcome analysis of antidepressant
treatment, 15 haplotypes were found to be associated
with the relative reduction in HAM-D21 score after
controlling for age, gender and baseline HAM-D21
score (Table 6). Among the 15 associated haplotypes,
2i nSLC6A3 and 3 in NTRK2 showed a correlation
with a nominal P<0.004 in desipramine-treated
patients, and 2 in SLC6A2 showed an association
with a nominal P<0.008 in fluoxetine-treated pa-
tients. The most significant association was found
between NTRK2 haplotype CAG (rs2289658,
rs2289657 and rs2289656) and relative reduction of
HAM-D21 score with a nominal P=0.0002 and an
effect size of squared R=0.20 (Table 6).
Discussion
In this study, we analyzed the fine structure of seven
genes that are relevant to the pathophysiology of MDD
or to antidepressant response at four sequential
levels: (1) entry into the brain, (2) binding to
monoaminergic transporters, and (3) distal effects at
the transcription level, resulting in (4) changes in
neurotrophin and neuropeptide receptors. We ob-
served new alleles in all seven genes in Mexican-
Americans. We described a total of 204 novel SNPs
(Table 1), which almost doubled the number of
reported SNPs in these genes that was detected in
these individuals (total of dbSNPs was 215). The
number of novel SNPs identified in these Mexican-
American subjects ranged from 12 to 57, and in the
case of CREB1, the total number of SNPs tripled from
6 to 18. Most of the novel SNPs reported here had
MAF lower than 5% (Supplementary Table 1). Higher
nucleotide diversity was found in the exonic regions
of these genes, particularly in UTRs (Figure 2b). Only
a small number of the novel SNPs were in coding
regions
19 and of those <40% (7) were non-synon-
ymous. Analyses of HapMap data on four ethnic
groups found different allele frequencies, with the
greatest differences between Mexican Americans and
Africans (Figure 1d).
Our analyses revealed nominal associations of eight
SNPs and four haplotypes with susceptibility for
MDD; those SNPs and haplotypes were located in four
genes, ABCB1, CREB1, NTRK2 and SLC6A3.I n
addition, eight SNPs in SLC6A4 and one haplotype
Table 5 Haplotypes associated with depression or clinical remission after 8-week antidepressant treatment
Sample Gene Block no. Haplotype
a Frequency w
2 d.f. P
Case Control
MDD patients and
healthy controls
CREB1 Block 1 GCACGG 0.003 0.018 5.71 1 0.02
SLC6A3 Block 1 CGTGCGGT 0.089 0.134 4.83 1 0.03
ABCB1 Block 2 GCACACACGAGAC 0.060 0.028 6.12 1 0.01
NTRK2 Block 1 GTTAGGGCA 0.094 0.133 3.96 1 0.05
SLC6A2 Block 3 ACCAGA 0.004 0.017 3.98 1 0.05
Remitter Non-remitter
MDD patients treated with
desipramine or fluoxetine
ABCB1 Block 1 ACA 0.101 0.029 4.72 1 0.03
NTRK2 Block 3 TCG 0.839 0.717 5.63 1 0.02
SLC6A4 Block 1 TAGC 0.006 0.047 5.11 1 0.02
Block 1 TAGA 0.048 0.003 4.92 1 0.03
Block 2 ATTGTAACC 0.028 0.081 4.00 1 0.05
MDD patients treated
with desipramine
ABCB1 Block 1 ACA 0.132 0.018 5.31 1 0.02
NTRK2 Block 3 TCG 0.865 0.679 6.35 1 0.01
Block 3 CAG 0.045 0.177 5.74 1 0.02
SLC6A2 Block 3 GCCAGT 0.134 0.012 6.79 1 0.009
MDD patients treated
with fluoxetine
ABCB1 Block 2 GCGCACACGAGAC 0.503 0.682 4.08 1 0.04
SLC6A4 Block 1 TAGC 0.000 0.085 8.37 1 0.004
Abbreviations: ABCB1, ATP-binding cassette subfamily B member 1; CREB1, cyclic AMP-responsive element binding protein
1; MDD, major depressive disorder; NTRK2, neurotrophic tyrosine kinase type 2 receptor; SNP, single nucleotide
polymorphism.
aLetters with underline indicate the SNPs also showing an association with a nominal P<0.05 in the corresponding
SNP-based analysis.
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Molecular Psychiatryin SLC6A2 were also associated with MDD (Tables 2
and 5). However, some of these SNPs were not very
common (MAF <0.03 in controls).
Nominal associations with several polymorphisms
were also found for treatment response of 142 MDD
patients who completed 8-week antidepressant
treatment with desipramine or fluoxetine. Discrete
outcome analyses (remitters vs non-remitters) showed
that SNPs and haplotypes in ABCB1 and NTRK2 were
associated with response. Variation in SLC6A2 and
one haplotype in SLC6A4 were also associated with
remission status. Quantitative outcome analyses
showed that SNPs and haplotypes in ABCB1, NTRK2
and SLC6A2 were associated with relative HAM-D21
score reduction, but only two SNPs and one haplo-
type in NTRK2 remained significant for desipramine
treatment after correcting for multiple testing.
Our data show that variations in six out of seven
genes were associated with MDD or antidepressant
response. Briefly, (i) SNPs in ABCB1 (located at
7q21.1), which is also called multidrug resistance 1,
were associated with MDD and antidepressant re-
sponse. ABCB1 encodes a large transmembrane
transporter protein that acts as an active efflux pump
transporting a wide range of drugs from the brain to
the blood. Polymorphisms in this gene have been
reported to predict the response to antidepressant
treatment to drugs that are substrates for this
transporter.
21 (ii) SNPs in the CREB1 gene were
associated with MDD. CREB (cyclic AMP response
element-binding protein, located at 2q32.2-q34) en-
codes a transcription factor that modulates key
growth factors important for synaptogenesis and
neurogenesis. Sequence variations in the promoter
and intronic regions of the CREB1 gene have
previously been described to be cosegregated with
mood disorders in women.
22 3) SNPs in NTRK2
(located at 9q22.1) were associated with susceptibility
to MDD and antidepressant response. Furthermore,
two SNPs and one haplotype in NTRK2 continued to
be significantly associated with relative reduction
of HAM-D21 scores in the desipramine-treated group,
after controlling for age, gender and baseline HAM-
D21 scores. NTRK2, also known as tyrosine kinase
receptor B, and its ligand, brain-derived neurotropic
factor, regulate short- and long-term synaptic func-
tions and neural plasticity. NTRK2 variants have
been recently associated with obsessive-compulsive
Table 6 Haplotypes associated with relative reduction of HAM-D21 score after 8-week antidepressant treatment
Medication Gene Block no. Haplotype
a N b
b R
2 c tP
Desipramine
or fluoxetine
SLC6A3 Block 1 CGCGAAGT 133 40.95 0.07 3.14 0.002
Block 1 CGTGCGGT 133 17.01 0.05 2.69 0.008
ABCB1 Block 3 TCTTACCGATCG 141 27.17 0.05 2.58 0.01
NTRK2 Block 2 GCACGCCATTGGCAC 140  5.85 0.03  2.20 0.03
Block 3 CAG 132 14.58 0.07 3.16 0.002
Block 3 TCG 132  7.49 0.04  2.35 0.02
Block 4 CA 134  11.22 0.04  2.36 0.02
SLC6A2 Block 1 GATGAT 140  15.88 0.04  2.46 0.01
Block 1 TAGGGT 140 10.00 0.03 2.10 0.04
Desipramine SLC6A3 Block 1 CGTGCGGT 65 36.51 0.15 3.29 0.002
Block 1 CGCGAGGT 65  15.77 0.12  2.99 0.004
NTRK2 Block 2 GAACCCGCTCGGTAC 66 13.69 0.09 2.47 0.02
Block 2 GCACGCCATTGGCAC 66  9.68 0.08  2.30 0.02
Block 3 CAG 64 24.02 0.20 3.90 0.0002
Block 3 TCG 64  11.55 0.09  2.49 0.02
Block 4 CA 65  20.49 0.15  3.29 0.002
Block 4 TA 65 22.05 0.13 3.02 0.004
SLC6A4 Block 1 GAGA 67 10.65 0.08 2.37 0.02
Fluoxetine NTRK2 Block 2 CCACCCCACCATCTC 72 14.21 0.06 2.16 0.03
SLC6A2 Block 1 GATGAT 73  18.92 0.10  2.88 0.005
Block 1 TAGGGT 73 14.54 0.10 2.73 0.008
Block 2 GT 67  13.66 0.06  2.03 0.05
SLC6A4 Block 1 GAAA 74 28.05 0.06 2.08 0.04
Abbreviation: ABCB1, ATP-binding cassette subfamily B member 1; HAM-D21, 21-item Hamilton Depression Rating Scale;
NTRK2, neurotrophic tyrosine kinase type 2 receptor; SNP, single nucleotide polymorphism.
aLetters with underline indicate the SNPs also showing an association with a nominal P<0.05 in the corresponding
SNP-based analysis.
bb: regression coefficient after controlling for age, gender and baseline HAM-D21 score.
cR
2: proportion variance explained.
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23 (iv) SNPs in SLC6A2
(noradrenaline transporter, located at 16q12.2) were
associated with remission status and relative reduc-
tion of HAM-D21 scores, and one haplotype in this
gene (ACCAGA) was associated with MDD. SLC6A2
gene encodes a transporter, which regulates
norepinephrine (noradrenaline) homeostasis and the
reuptake of norepinephrine into presynaptic
nerve terminals.
24 SLC6A2 polymorphisms have been
reported to be associated with depression
25,26 and
response to antidepressants.
27,28 (v) SNPs or haplo-
types in SLC6A3 (dopamine transporter or DAT1,
located at 5p15.33), which encodes a transporter that
is important in dopaminergic neurotransmission,
were associated with risk for MDD or relative
reduction of HAM-D21. This transporter mediates
the active re-uptake of synaptic dopamine.
29 Varia-
tions in this gene have already been implicated in
susceptibility for mood disorders
30,31 and antidepres-
sant action.
32 Other neuropsychiatric conditions have
also been associated with SLC6A3, such as parkin-
sonism,
33 attention-deficit hyperactivity disor-
der,
34,35,36 Tourette’s syndrome and addictive
behavior.
37,38 6) SLC6A4 (serotonin transporter,
located at 17q11.1-q12) encodes a transporter, which
mediates antidepressant action, and behavioral
effects of cocaine and amphetamines. Sequence
variations in SLC6A4 have been extensively queried
and they may be associated with several neuropsy-
chiatric conditions, including MDD,
39,40,41 anxiety-
related personality traits
42 and antidepressant re-
sponse.
43,44 Our findings support that variations in
SLC6A4 are associated with MDD risk. Haplotypes in
SCL6A4 have also been associated with remission
status and reduction of HAM-D21 scores.
The analyses presented here have not shown that
variations in CRHR1 (located at 17q12-q22) gene are
associated with susceptibility to MDD or antidepres-
sant response. It can be noted that the current
analyses have not taken anxiety levels into considera-
tion. CRHR1 encodes the receptor of CRH, a key stress
hormone that regulates the response to stress at the
behavioral, immune, autonomic and neuroendocrine
levels, through the activation of the hypothalamic–
pituitary–adrenalaxis. Polymorphisms in CRHR1
were reported to be associated with antidepressant
response, but only when anxiety scores are taken in
consideration,
45,46 and with seasonal pattern and
early onset of first depressive episode.
47
In summary, we show that substantial levels of
sequence variation, especially those that are not very
common (MAF >5%), are likely to be found in
candidate genes in an ethnically defined and under-
studied group. In this population group, for example,
half of the SNPs detected were novel. Therefore,
deep sequencing data may be relevant to our under-
standing of common and complex disorders, such as
major depression, particularly in minority populations.
Our analyses showed that several sequence variations
and haplotypes in six out of seven selected genes
were nominally associated with MDD risk and/or
antidepressant treatment response and that after
controlling for age, gender and baseline HAM-D21
score, as well as correcting for multiple testing, there
was a significant association of antidepressant re-
sponse with two NTRK2-coding SNPs and one
haplotype. Our findings suggest that these variants
may be implicated in the pathophysiology of MDD.
The Mexican Americans are the most rapidly growing
population group in the United States, but remain
under represented in research studies. These results
highlight the importance of direct re-sequencing of
key candidate genes in ethnic minority groups in
order to discover novel genetic variants that cannot be
simply inferred from existing databases.
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